Camille Schubert

Research Interests

Surgical and Health Systems Innovation Translational Health Outcomes Health Economics Health Policy & Services Medical and Health Sciences Public Health and Health Services

Ms Camille Schubert

Grant-Funded Research Fellow

School of Public Health

College of Health

Camille Schubert - Senior Health Economist / Team LeaderMs Schubert is primarily involved in modelling health outcomes and costs associated with proposals for new listings on the Medicare Benefits Scheme, for the Medical Services Advisory Committee and supervision of the production of independent Commentaries for the Pharmaceutical Benefits Advisory Committee on applications made by industry to the Pharmaceutical Benefits Scheme. Her primary expertise and interest is health economic policy associated with funding of health technologies, pharmacoeconomics and the economics of co-dependent health technologies. Camille has been a consultant pharmacist to a wide range of health care institutions, including public and private, general and specialist hospitals, aged care facilities, correctional centres and drug information centres in rural, metropolitan and overseas settings. She was previously Director of Pharmacy at Modbury Hospital. Amongst other work, she has completed reviews for the World Health Organization on pharmaceutical finance and expenditure in selected Pacific island countries, and has been a member of a consultancy team reviewing aspects of hospital pharmacy for the South Australian state government.Qualifications:Master of Health Economics and Policy, Bachelor of Economics, Bachelor of Pharmacy

Date Position Institution name
2009 - ongoing Team Leader - Health Economics University of Adelaide
2005 - 2009 Senior Researcher - Health Economics University of Adelaide
2002 - 2004 Director of Pharmacy - Modbury Hospital Hospital Pharmacy Services / HPS Pharmacies
2001 - 2002 Drug Information Pharmacist (including Drugs in Pregnancy and Breastfeeding telephone advice line) (part-time) Womens' and Childrens' Hospital
2000 - 2000 Locum Hospital Pharmacist - England, Scotland Principal Locums
1997 - 2002 Consultant Pharmacist (various hospital and healthcare/aged care clients) Hospital Pharmacy Services / HPS Pharmacies

Date Institution name Country Title
2008 - 2012 University of Adelaide Australia Master of Health Economics and Policy
1997 - 2001 University of Adelaide Australia Bachelor of Economics
1993 - 1995 University of South Australia Australia Bachelor of Pharmacy

Year Citation
2026 Stern, C., Pollock, D., Barker, T., Holland, G. M., Hasanoff, S., Shrestha, N., . . . Munn, Z. (2026). Protocol for the Development of The Australian Motor Neurone Disease (MND) Guideline. Clinical and Public Health Guidelines, 3(1).
DOI
2025 Stern, C., Semendric, I., Shrestha, N., Beasley-Hall, J., Hasanoff, S., Barker, T., . . . Munn, Z. (2025). Guidelines addressing Motor Neurone Disease (MND): a scoping review. Neurodegenerative Disease Management, 16 pages.
DOI
2025 Schubert, C. M., Jackson, M. R., Barnett, C. P., Scott, H. S., Sullivan, T., Goodall, S., . . . Genomic Autopsy Study Research Network. (2025). Evaluating the Clinical Utility of Genomic Sequencing After Perinatal Death. Clinical Genetics, online(1), 13 pages.
DOI
2025 Barker, T. H., Holland, G., Schubert, C., Pollock, D., Stern, C., Shrestha, N., . . . Munn, Z. (2025). The Values and Preferences of People Living With Motor Neurone Disease (MND): A Systematic Review Protocol. Clinical and Public Health Guidelines, 2(4).
DOI
2024 Schubert, C., Milverton, J., Goodall, S., & Merlin, T. (2024). A systematic review to assess the utility of genomic autopsy using exome or genome sequencing in cases of congenital anomalies and perinatal death.. Genetics in Medicine, 26(7), 101159-1-101159-12.
DOI Scopus5 WoS5 Europe PMC4
2022 Roughead, E. E., Pratt, N. L., Parfitt, G., Rowett, D., Kalisch-Ellett, L. M., Bereznicki, L., . . . Lim, R. (2022). Effect of an ongoing pharmacist service to reduce medicine-induced deterioration and adverse reactions in aged-care facilities (nursing homes): a multicentre, randomised controlled trial (the ReMInDAR trial). AGE AND AGEING, 51(4), 1-9.
DOI Scopus24 WoS21 Europe PMC25
2020 Lim, R., Bereznicki, L., Corlis, M., Kalisch Ellett, L. M., Kang, A. C., Merlin, T., . . . Roughead, E. E. (2020). Reducing medicine-induced deterioration and adverse reactions (ReMInDAR) trial: study protocol for a randomised controlled trial in residential aged-care facilities assessing frailty as the primary outcome.. BMJ Open, 10(4), e032851.
DOI Scopus12 WoS12 Europe PMC11
2017 Schubert, C. M. (2017). Regulatory and government funding agency consideration of monetary costs to the cancer patient. Cancer Forum, 41(2), 10-15.
Scopus1 WoS1
2013 Merlin, T., Farah, C., Schubert, C., Mitchell, A., Hiller, J., & Ryan, P. (2013). Assessing personalized medicines in Australia: A national framework for reviewing codependent technologies. Medical Decision Making, 33(3), 333-342.
DOI Scopus49 WoS41 Europe PMC32

Year Citation
2025 Vogan, A., Milverton, J., Allani, P., Carter, D., Newton, S., Parsons, J., & Schubert, C. (2025). Economic evaluation of newborn bloodspot screening for sickle cell disease to inform public funding decision-making. In https://ahes.org.au/ahes-conference-2025/. Canberra.

Year Citation
2024 Schubert, C., Jackson, M., Barnett, C., Scott, H., Goodall, S., & Merlin, T. (2024). Exome or genome sequencing for perinatal autopsy: A 'before and after' change-in-management study. Poster session presented at the meeting of Human Genetics Society of Australasia (HGSA) Annual Meeting. Gold Coast, Queensland, Australia.
2018 Mittal, R., & Schubert, C. M. (2018). COST-EFFECTIVENESS OF CRYOPRESERVING SPERM IN MALES UNDERGOING GONADOTOXIC THERAPY. Poster session presented at the meeting of VALUE IN HEALTH. ELSEVIER SCIENCE INC.
DOI
2018 Milverton, J., Newton, S., Vogan, A., Schubert, C., & Merlin, T. (2018). Methodology to assess a predictive test for breast cancer recurrence. Poster session presented at the meeting of Abtracts of the Annual Meeting HTAi 2018. Vancouver, Canada: Health Technology Assessment international (HTAi).
2018 Vogan, A., & Schubert, C. M. (2018). A COST-UTILITY ANALYSIS OF PROSIGNA®, A 50 GENE TEST FOR PREDICTING BREAST CANCER RECURRENCE, IN THE AUSTRALIAN SETTING. Poster session presented at the meeting of VALUE IN HEALTH. ELSEVIER SCIENCE INC.
DOI
2017 Schubert, C. M., Lee, K., Knies, S., Gerber-Grote, A., & Moseley, O. (2017). PN.46 Health economic guidelines: Hot topics in economic methods from INAHTA member agencies - Panel Session. Poster session presented at the meeting of 14th Health Technology Assessment international (HTAi) Annual Meeting. Rome, Italy.
2017 Mittal, R., & Schubert, C. M. (2017). Multiple populations in a single evaluation of CFTR testing. Poster session presented at the meeting of the 14th Annual Health Technology Assessment international (HTAi) Conference. Rome, Italy.
2017 Vogan, A., Schubert, C., & Merlin, T. (2017). The Impact Of Treatment Timing On The Cost-Effectiveness Of Tests. Poster session presented at the meeting of the 14th Annual Health Technology Assessment international (HTAi) Conference. Rome, Italy.
2016 Vogan, A., Schubert, C., Newton, S., & Merlin, T. (2016). What are we missing by limiting the outcome of cost effectiveness analyses of diagnostic tests to cost per correct result?. Poster session presented at the meeting of the 13th Annual Health Technology Assessment international (HTAi) Conference. Tokyo, Japan.
2016 Schubert, C., & Newton, S. (2016). Assessing value-for-money for orphan drugs; the mismatch of applied theory methods, economic theory and available data. Poster session presented at the meeting of http://meeting.htai.org/events/tokyo2016/agenda-4023afce0ec04ab387500e87f0a6a42d.aspx. Tokyo, Japan.
2014 Merlin, T. L., & Schubert, C. (2014). Evaluating Medical Tests for Coverage Decisions Using the Linked Evidence Approach. Poster session presented at the meeting of the 11th Annual Health Technology Assessment international (HTAi) Conference. Washington, DC, USA.
2014 Vogan, A., Schubert, C., Parsons, J., Morona, J., & Merlin, T. (2014). The impact of an imperfect diagnostic reference standard on the cost-effectiveness of HbA1c testing in the diagnosis of Type II diabetes. Poster session presented at the meeting of the 11th Annual Health Technology Assessment international (HTAi) Conference. Washington D.C., USA.
2014 Vogan, A., Schubert, C., Parsons, J., Morona, J., & Merlin, T. (2014). Assessing the cost-effectiveness of HbA1c testing in the diagnosis of Type II diabetes and the impact of an imperfect diagnostic reference standard. Poster session presented at the meeting of the 36th Annual North American Meeting Society for Medical Decision Making (SMDM). Miami, USA.
2014 Kessels, S., Schubert, C., Newton, S. S., & Merlin, T. (2014). Assessment of catheter-free (wireless) ambulatory oesophageal pH monitoring for Gastro-esophageal Reflex Disease (GORD). Poster session presented at the meeting of Health Technology Assessment International. Washington, DC.
2014 Butler, J., Norris, S., & Schubert, C. M. (2014). W6 Panel Session: Reality bites - MSAC Application failures - investigating pathways forward. Poster session presented at the meeting of ARCS 2014 Canberra Congress. Canberra: Association of Regulatory and Clinical Scientists (ARCS) Australia.
2014 Butler, J., Norris, S., & Schubert, C. M. (2014). W6 Panel Session: Reality bites - MSAC Application failures - investigating pathways forward. Poster session presented at the meeting of ARCS 2014 Canberra Congress. Canberra: Association of Regulatory and Clinical Scientists (ARCS) Australia.
2013 Newton, S., Wang, S., Schubert, C., & Merlin, T. (2013). One small step for an individual, one giant leap for their family: considerations required for assessing the cost effectiveness of genetic tests. Poster session presented at the meeting of the 10th Annual Health Technology Assessment international (HTAi) Conference. Seoul, South Korea.
2012 Merlin, T. L., Farah, C., Schubert, C., Mitchell, A., Hiller, J. E., & Ryan, P. (2012). How to assess personalised medicines for reimbursement decisions? Developing a framework for Australia. Poster session presented at the meeting of the 9th Annual Health Technology Assessment international (HTAi) Conference. Bilbao, Spain.
1996 Schubert, C. M., Veljkovic, D., Kotasek, D., Sage, E., Pegoli, V., & Bolton, A. (1996). Alternative Therapy use in Cancer Patients. Poster session presented at the meeting of Clinical Oncological Society of Australia (COSA) 23rd Annual Scientific Meeting. Brisbane, Australia.

Year Citation
2022 Morona, J., Mittal, R., Laka, M., Parsons, J., & Schubert, C. (2022). Whole Genome Sequencing for the diagnosis of mitochondrial disease. (MSAC APplication 1675). Canberra, ACT: Commonwealth of Australia, Canberra, ACT.
2021 Mittal, R., Milverton, J., Schubert, C., & Parsons, J. (2021). Review of immunoglobulin use for Chronic Inflammatory Demyelinating Polyneuropathy (MSAC Application no 1564 re-submission assessment report). Canberra, ACT: Commonwealth of Australia 2021.
2020 Milverton, J., Mittal, R., Bellman, S., Parsons, J., & Schubert, C. (2020). Antibody testing for neuromyelitis optica spectrum disorder (NMOSD). Commonwealth of Australia, Canberra, ACT.
2020 Tamblyn, D., Vogan, A., Parsons, J., Schubert, C., Bellman, S., & Carter, D. (2020). Technical report to supplement clinical utility card for genetic testing for diagnosis of inheritable cardiomyopathies (MSAC Application 1599). Canberra: Commonwealth of Australia.
2020 Tamblyn, D., Vogan, A., Parsons, J., Schubert, C., Bellman, S., & Carter, D. (2020). Clinical utility card for heritable cardiomyopathies.
2020 Milverton, J., Bellman, S., Schubert, C., Carter, D., Newton, S., Parsons, J., & Merlin, T. (2020). Photodynamic therapy for non-melanoma skin tumours (Document Number MTAR 39/2020/E).
2020 Newton, S., Mittal, R., Hill, H., Milverton, J., Carter, D., & Schubert, C. (2020). Technical report to supplement clinical utility card for genetic testing for diagnosis of inheritable cardiac rhythm disorders (MSAC Application 1598). Canberra: Commonwealth of Australia.
2020 Newton, S., Mittal, R., Hill, H., Milverton, J., Carter, D., & Schubert, C. (2020). Clinical utility card for genetic testing for diagnosis of inheritable cardiac rhythm disorders. Canberra: Commonwealth of Australia.
2019 Wyndham, A., Vogan, A., Newton, S., & Schubert, C. (2019). Immunoglobulin for acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (MSAC application 1565). Commonwealth of Australia.
2019 Kessels, S., Newton, S., Vogan, A., Mittal, R., Schubert, C., Carter, D., . . . Merlin, T. (2019). Clinical utility card for heritable mutations associated with familial hypercholesterolaemia (MSAC Application 1534). Canberra: Commonwealth of Australia.
2019 Kessels, S., Newton, S., Vogan, A., Mittal, R., Schubert, C., Carter, D., . . . Merlin, T. (2019). Technical report to supplement clinical utility card for heritable mutations associated with familial hypercholesterolaemia (MSAC Application 1534). Canberra: Commonwealth of Australia.
2019 Kessels, S., Mittal, R., Morona, J., Schubert, C., & Newton, S. (2019). Faecal calprotectin testing in patients suspected of inflammatory bowel disease (IBD) presenting to primary care. (MSAC Application 1353.1). Canberra, ACT.
2018 Milverton, J., Vogan, A., Newton, S., Parsons, J., Schubert, C., & Merlin, T. (2018). Extended half-life clotting factor concentrates for the treatment of haemophilia A and B (MSAC Application 1511).
2018 Milverton, J., Vogan, A., Parsons, J., Kessels, S., Carter, D., Schubert, C., . . . Merlin, T. (2018). Genetic deletion testing for alpha thalassaemia (MSAC Application 1531). Canberra: Commonwealth of Australia.
2018 Milverton, J., Mittal, R., Carter, D. A., Kessels, S., Newton, S., Schubert, C., . . . Merlin, T. (2018). Processing and cryopreservation of ovarian tissue prior to or after gonadotoxic treatment to preserve fertility in females for the future (MSAC Application 1435 Part B, Assessment Report). Canberra: Commonwealth of Australia.
2018 Kessels, S., Mittal, R., Morona, J., Newton, S., Schubert, C., Milverton, J., & Merlin, T. (2018). Anti-Müllerian hormone testing for female patients preceding or following gonadotoxic treatment (MSAC 1434).
2018 Mittal, R., Kessels, S., Morona, J., Newton, S., Vogan, A., & Schubert, C. (2018). Heritable mutations which increase risk in colorectal and endometrial cancer - Lynch syndrome and adenomatous polyposis syndrome. Economic and financial evaluation. (MSAC clinical utility card 1504). Canberra: Commonwealth of Australia.
2017 Morona, J., Mittal, R., Newton, S., Salinger, K., Carter, D. A., Schubert, C., & Merlin, T. (2017). Processing and cryopreservation of semen, sperm and testicular tissue prior to or after gonadotoxic treatment to preserve future fertility (MSAC 1435 Part A, Assessment Report). Canberra: Commonwealth of Australia.
2017 Milverton, J., Vogan, A., Newton, S., Schubert, C., & Merlin, T. (2017). 50 gene signature assay for predicting breast cancer recurrence (MSAC Application 1473).
2017 Mittal, R., Kessels, S., Newton, S., Milverton, J., Parsons, J., Morona, J., . . . Merlin, T. (2017). Testing for hereditary mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene - Resubmission (MSAC application 1216.1). Canberra: Commenwealth of Australia.
2016 Morona, J., Vogan, A., Kessels, S., Newton, S., Pridham, L., Ellery, B., . . . Merlin, T. (2016). Magnetic resonance imaging of patients with suspected non-ischaemic cardiomyopathies (MSAC 1432). Canberra.
2016 Tamblyn, D., Schubert, C., & Merlin, T. L. (2016). Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee, Version 5.0. Commonwealth of Australia.
2016 Kessels, S., Mittal, R., Morona, J., Newton, S., Ellery, B., Milverton, J., . . . Merlin, T. (2016). Magnetic resonance imaging of patients with suspected (non-ischaemic) dilated cardiomyopathies (MSAC Application no. 1393). Canberra, ACT: Commonwealth of Australia.
2016 Milverton, J., Mittal, R., Parsons, J., Schubert, C., & Newton, S. (2016). Microwave tissue ablation for primary and secondary liver cancer (MSAC Application no. 1402). Australia: Commonwealth of Australia.
2015 Kessels, S., Morona, J., Mittal, R., Vogan, A., Newton, S., Schubert, C., & Merlin, T. (2015). Testing for hereditary mutations in the Cystic Fibrosis conductance Transmembrane Regulator (CFTR) gene (1216). http://www.msac.gov.au/internet/msac/publishing.nsf/Content/B1083E11E4A3006BCA257BCB0081849E/$File/1216-MSAC-CA-CFTR.pdf: Commonwealth of Australia.
2015 Newton, S., Ellery, B., Fischer, S., Farah, C., Gum, D., Liufu, Z., . . . Merlin, T. L. (2015). Life Saving Drugs Programme Review: Technical Assessment. Canberra, ACT: Australian Government Department of Health.
2014 Kessels, S., Schubert, C., Parsons, J., Morona, J. K., & Merlin, T. (2014). Bone mineral density analyses using dual energy x-ray absorptiometry (DXA) for women in their 50th year (MSAC Application number 1162). Canberra, ACT.: Commonwealth of Australia.
2014 Morona, J. K., Vogan, A., Kessels, S., Gum, D., Milverton, J., Parsons, J., . . . Merlin, T. (2014). Nucleic acid amplification testing for active mycobacterial infection (MSAC Application number 1234). Canberra, ACT.: Commonwealth of Australia.
2014 Parsons, J., Vogan, A., Morona, J. K., Schubert, C., & Merlin, T. (2014). HBA1c test for the diagnosis of diabetes mellitus (MSAC Application 1267). Canberra, ACT.: Commonwealth of Australia.
2014 Kessels, S., Schubert, C., Newton, S., & Merlin, T. (2014). Catheter-free (wireless) ambulatory oesophageal pH monitoring for gastro-oesophageal reflux disease (GORD) (1203). Canberra, ACT: Commonwealth of Australia.
2013 Newton, S., Schubert, C., Morona, J. K., Fitzgerald, P., & Merlin, T. (2013). Genetic testing for hereditary mutations in the RET gene. (MSAC Application 1152). Canberra, ACT.: Commonwealth of Australia.
2011 Farah, C., Schubert, C., & Merlin, T. L. (2011). Detection of K-RAS mutation status to inform treatment with cetuximab (Erbitux). Canberra, ACT.
2011 Schubert, C., Farah, C., & Merlin, T. L. (2011). Detection of EGFR mutation status to inform treatment with gefitinib (Iressa). Canberra, ACT: Commonwealth of Australia.

Contract Research - Public Sector Funding

Date Project/No. Investigators Funding Body Amount
2019-25

Services for Health Technology Assessment, Research Support and Other Services.

 Merlin T, Newton S, Parsons J, Tamblyn D, Schubert C, Wang S, Carter D, Marshall H, Gold M. Department of Health (Technology Access and Assessment Division; and Therapeutic Goods Administration), Australian Government. to $12 million over 6 years
2018 Review of the processes and procedures to support the Australian Technical Advisory Group on Immunisation (ATAGI) Merlin T, Parsons J, Schubert C

Department of Health, Australian Government

 $56,019
2017-2018 Develop an HTA review pathway and methodology Merlin T, Schubert C.

Department of Health, Australian Government

Technology Access and Assessment Division

 $56,324
2017-2020 National Blood Authority Merlin T, Newton S, Schubert C, Salinger K. Department of Health, Australian Government $39,428
2016-2020 External evaluation of industry submissions to the Pharmaceutical Benefits Advisory Committee Merlin T, Wang S, Schubert C, Tamblyn D. Department of Health (Pharmaceutical Benefits Branch), Australian Government $3,851,303 (minimum)
2015-2016 Review of Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee AHTA - Merlin T, Tamblyn D, Schubert C ; Consultants - Karnon J, Afzali H, Sculpher M, Drummond M, Roughead L, Sullivan T.; Editors - Biotext (Editorial) – Salisbury J, Irish, J. Department of Health (Pharmaceutical Benefits Branch) $539,842
2015-2018 Provision of Health Technology Assessment Services to the Medical Services Advisory Committee (MSAC HTA Panel) AHTA - Merlin T, Newton S, Schubert C, Parsons J, Street J, Carter D, Sullivan T. ; JBI – Aromataris E et al. Department of Health (Medicare Benefits Branch) ~approx $3 million over 3 years
2013-2015 Provision of Health Technology Assessment Services to the Medical Services Advisory Committee (MSAC HTA Panel) Merlin T, Newton S, Schubert C, Parsons J, Street J. Department of Health and Ageing (Medicare Benefits Branch) $2,057,250
2012-2016 External evaluation of industry submissions to the Pharmaceutical Benefits Advisory Committee Merlin T, Moss J, Wang S, Schubert C. Department of Health and Ageing (Pharmaceutical Benefits Branch) $5,455,151

 

Internal support for trials, studies and contracted research

Date Project description, Investigators Services provided Institution/Funding Amount
2018 - 2020

ReMInDAR Trial - Reducing Medicine Induced Deterioration and Adverse Reactions

Roughead E (UniSA), Merlin T (Adelaide University AHTA), Olds T / Parfitt G (UniSA ARENA), Bereznicki L (University of Tasmania), Pratt N (UniSA), Boylan J / Kang A (Southern Cross Care SA NT), Corlis M (Helping Hand Aged Care Inc), Phillips A (Terry White Chemmart), Lim R (UniSA)
  • Health economic study design and analysis plan
  • Health economic data management
  • Health economic analysis
 Pharmacy Trial Program - Tranche 2 $2,847,926
2016-2017

Health technology assessment for submission to the Medical Services Advisory Committee

Merlin T
  • Advice and supervision of economic and financial modelling and analyses
 NanoString Diagnostics Pty Ltd $149,374
2014-2015

Review of Life Saving Drugs Program

Merlin T
  • Health economic data analysis
  • health economic policy analysis
 Postmarket Reviews of PBS Medicines, Pharmaceutical Benefits Branch, Department of Health and Ageing $326,505
2008-2012

External evaluation of vaccine and pharmaceutical submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) for funding under the Pharmaceutical Benefits Scheme

Merlin T, Moss J, Hiller J.
  • Supervision/preparation of Commentaries evaluating industry submissions to the PBAC
 Department of Health and Ageing (Pharmaceutical Benefits Branch) $4,045,753
2008-2012

Provision of health technology assessment and research related support services, including independent evaluation of services under consideration by the Medical Services Advisory Committee (MSAC) for Medicare funding.

Merlin T, Hiller J, Braunack-Mayer A, Elshaug A, Karnon J, Moss J, Street J.
  • Health economic analyses and support
 Department of Health and Ageing (Medical Benefits Division) $2,500,000
2010

Development of a framework and methodology for evaluating co-dependent technologies (personalised medicines).

Merlin T
  • Health economics support and economic evaluation methodology
 Department of Health and Ageing (Medicare Benefits Division and Pharmaceutical Benefits Division) $51,486
2007-2009

External evaluation of vaccine submissions to the Pharmaceutical Benefits Advisory Committee

Merlin T, Hiller J
  • Evaluation of industry submissions for vaccines and preparation of Commentaries on vaccine for PBAC.
 Department of Health and Ageing (Pharmaceutical Benefits Branch) $394,027
2004-2008 External evaluation of industry submissions to the Pharmaceutical Benefits Advisory Committee.

Moss J, Hiller J, Merlin T, Tonkin A.
  • Evaluation of industry submissions and preparation of Commentaries for PBAC
 Department of Health and Ageing (Pharmaceutical Benefits Branch) $2,618,082

Teaching Activities 

Camille currently teaches the post graduate Health Economics course within the Masters of Public Health. She also provides guest teaching on topics such as; introduction to health economics and/or economic modelling; interpretation and/or critical appraisal of health economic analyses, and health economics of co-dependent technologies within other undergraduate and post-graduate courses for MBBS, health science and public health students.

Date Role Committee Institution Country
2016 - ongoing Member South Australian Medicines Evaluation Panel Government of South Australia Australia
2002 - 2004 Member Drug and Therapeutics Committee Modbury Public Hospital Australia
2002 - 2004 Member South Australian Therapeutics Advisory Group (SATAG) South Australian Public Hospitals (incl Modbury Public Hospital) Australia
1997 - 1999 Member SHPA SA (State Branch) Committee Society of Hospital Pharmacists of Australia Australia

Date Role Membership Country
2017 - ongoing Member Health Technology Assessment International Australia
1997 - ongoing Member Pharmacy Board of South Australia - Registered Pharmacist Australia
1996 - 1999 Member Society of Hospital Pharmacists of Australia Australia

Date Institution Department Organisation Type Country
2018 - 2023 National Health and Medical Research Council National Health and Medical Research Council Health services and related Australia
2018 - 2018 SAHMRI (South Australian Health and Medical Research Institute) Australian Bragg Centre for Proton Therapy and Research Health services and related Australia
2013 - 2016 National Health and Medical Research Council Health Advice Panel member, services relevant to the development and presentation of evidence based health advice. Health services and related Australia
2013 - 2014 Australian Government National Drugs and Poisons Scheduling Committee, Office of Health Protection, Department of Health and Ageing, Review of drug submissions to move from one Poisons Schedule to another. Health services and related Australia
2009 - 2012 Australian Government National Drugs and Poisons Scheduling Committee, Office of Health Protection, Department of Health and Ageing, Review of drug submissions to move from one Poisons Schedule to another. Health services and related Australia
2008 - 2010 Australian Government Department of Health and Ageing, Panel of Providers of Health Economics Services. Health services and related Australia

Date Topic Presented at Institution Country
2018 - ongoing Health Economics Workshop - Invited Speaker Adelaide EPSM 2018, Engineering and Physical Sciences in Medicine Australia
2017 - 2017 Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines Evaluator Workshop Canberra AHTA, presenting at request of Australian Government Department of Health Australia
2016 - 2016 Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines Review Submission Sponsor Workshop Sydney (3), Melbourne (2) AHTA, presenting at request of Australian Government Department of Health Australia
2013 - 2013 HTA Workshop for Government staff Woden, Canberra AHTA for the Australian Commonwealth Government Department of Health and Ageing Australia
2012 - 2012 Evaluating Co-dependent submissions to inform PBAC decision making Woden, Canberra AHTA for the Australian Commonwealth Government Department of Health Australia
2011 - 2011 A Brief Introduction to Health Technology Assessment (HTA) Woden, Canberra AHTA for the Australian Commonwealth Government Department of Health and Ageing Australia

Date Title Type Institution Country
2016 - 2016 Palliative Medicine Journal: Reviewer Peer Review University of Adelaide -
2014 - ongoing Moderator: Poster session Conference Review HTAi 2014 Annual Meeting, Washington DC United States
2014 - 2014 A model-based cost utility analysis of Inhaled corticosteroids (ICS) for the treatment of asthma in Sri Lanka Thesis Review University of Adelaide Australia

Connect With Me

External Profiles

Other Links